Guardant Health, Inc. (NASDAQ: GH) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $19.5B. The Maz Rating grades it against the other companies in its sector.
Guardant Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $144.03, Guardant Health, Inc. trades at 16.0x sales. Over the last twelve months it generated about $1.2B of revenue and a net loss of $473M. It runs a gross margin of 65.2%, an operating margin of -39.4% and a net margin of -37.9%. It shows return on equity of 249.0%, return on invested capital of -32.6% and a free cash flow yield of -1.1%. On the balance sheet: a debt-to-equity ratio of -6.13 and a current ratio of 3.60. Over the past 52 weeks the share price ranged from $74.55 to $191.05, with a beta of 1.66.
Guardant Health, Inc. does not currently pay a dividend.
31 Wall Street analyst ratings cover the stock: 30 Buy and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Guardant Health, Inc. (GH) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.79% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.67% / 30% · Interest income / Revenue 2.70% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 6.79% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.64% / 33% · Receivables / Mkt Cap (36m) 0.84% / 49% · Interest income / Revenue 2.70% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 6.79% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.64% / 33.33% · Receivables / Mkt Cap (24m) 0.84% / 33.33% · Interest income / Revenue 2.70% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 77.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 56.7% / 33.33% · Receivables / Avg Assets (4Q) 7.84% / 33.33% · Interest income / Revenue 2.70% / 5% | Fail |
| FTSE | Debt / Total Assets 79.7% / 33.33% · (Cash+ST Inv) / Total Assets 54.5% / 33.33% · (Cash+Recv) / Total Assets 64.3% / 33.33% · Interest income / Revenue 2.70% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Guardant Health, Inc. (GH) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Guardant Health, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.70% of each dividend: Guardant Health, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.